RASL12

Across TCGA pan-cancer cohorts, RASL12 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RASL12 data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher RASL12 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RASL12 expression acts as an unfavorable survival marker.

ESCA, STAD, and LUAD are the cancer types where RASL12 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.212	0.686	.008	30	view →
STAD	OS	Median	II,III,IV	0.183	0.660	.009	12	view →
LUAD	OS	Median	II,III,IV	0.090	0.709	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	OS	Median	IV	0.415	0.861	.014	6	view →
LUSC	DFS	Median	II,III,IV	0.185	0.709	.018	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RASL12–ESCA (OS)

Open the ESCA breakdown →